Literature DB >> 24627266

Evaluation of treatment outcomes for Stenotrophomonas maltophilia bacteraemia.

B Lakatos1, B Jakopp, A Widmer, R Frei, H Pargger, L Elzi, M Battegay.   

Abstract

OBJECTIVE: The goal of this study was to retrospectively collect data about treatment outcomes in patients diagnosed with Stenotrophomonas maltophilia bacteraemia over a period of 20 years and evaluate these data with respect to the efficacy of treatment options.
METHODS: The setting was a 700-bed tertiary care hospital in a large urban area. Hospital databases and medical records provided information about episodes of S. maltophilia, patient characteristics and treatment outcomes. Patients with at least one positive blood culture for S. maltophilia were included in the study. Data were analysed with respect to clinical improvement and mortality ≤30 days after the onset of infection. We compared patient characteristics, laboratory values and treatments by using the Chi-square or Fisher's exact tests and the Mann-Whitney test.
RESULTS: We investigated 27 patients with S. maltophilia bacteraemia. The focus of infection was a central venous catheter in 18 (67 %) cases. The 30-day mortality rate was 11 %. All patients who were treated with an antibiotic that was effective in vitro against the pathogen recovered clinically and survived ≥30 days after the onset of infection. The most frequently used antibiotic was trimethoprim-sulfamethoxazole administered alone or in combination with a fluoroquinolone.
CONCLUSIONS: Despite the fact that S. maltophilia is resistant to multiple antibiotics, the prognosis for patients with S. maltophilia bacteraemia is good when they are treated with antibiotics that are effective against this pathogen in vitro.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24627266     DOI: 10.1007/s15010-014-0607-3

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  11 in total

1.  Emerging importance of multidrug-resistant Acinetobacter species and Stenotrophomonas maltophilia as pathogens in seriously ill patients: geographic patterns, epidemiological features, and trends in the SENTRY Antimicrobial Surveillance Program (1997-1999).

Authors:  A C Gales; R N Jones; K R Forward; J Liñares; H S Sader; J Verhoef
Journal:  Clin Infect Dis       Date:  2001-05-15       Impact factor: 9.079

2.  CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting.

Authors:  Teresa C Horan; Mary Andrus; Margaret A Dudeck
Journal:  Am J Infect Control       Date:  2008-06       Impact factor: 2.918

3.  Comparison of various in vitro susceptibility methods for testing Stenotrophomonas maltophilia.

Authors:  K C Carroll; S Cohen; R Nelson; D M Campbell; J D Claridge; M W Garrison; J Kramp; C Malone; M Hoffmann; D E Anderson
Journal:  Diagn Microbiol Infect Dis       Date:  1998-11       Impact factor: 2.803

4.  Attributable mortality of Stenotrophomonas maltophilia bacteremia.

Authors:  Esin Senol; Jeffrey DesJardin; Paul C Stark; Laurie Barefoot; David R Snydman
Journal:  Clin Infect Dis       Date:  2002-05-24       Impact factor: 9.079

Review 5.  Antimicrobial therapy for Stenotrophomonas maltophilia infections.

Authors:  A C Nicodemo; J I Garcia Paez
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2007-04       Impact factor: 3.267

6.  Bloodstream infections caused by Stenotrophomonas maltophilia: a seven-year review.

Authors:  M Garazi; C Singer; J Tai; C C Ginocchio
Journal:  J Hosp Infect       Date:  2012-04-10       Impact factor: 3.926

7.  A comparison of adverse drug reactions between high- and standard-dose trimethoprim-sulfamethoxazole in the ambulatory setting.

Authors:  Ann T Nguyen; Chris A Gentry; Rona Z Furrh
Journal:  Curr Drug Saf       Date:  2013-04

8.  Bacteremia due to Stenotrophomonas (Xanthomonas) maltophilia: a prospective, multicenter study of 91 episodes.

Authors:  R R Muder; A P Harris; S Muller; M Edmond; J W Chow; K Papadakis; M W Wagener; G P Bodey; J M Steckelberg
Journal:  Clin Infect Dis       Date:  1996-03       Impact factor: 9.079

9.  Stenotrophomonas maltophilia: an emerging opportunist human pathogen.

Authors:  W John Looney; Masashi Narita; Kathrin Mühlemann
Journal:  Lancet Infect Dis       Date:  2009-05       Impact factor: 25.071

10.  Clinical characteristics of Stenotrophomonas maltophilia infection in hematopoietic stem cell transplantation recipients: a single center experience.

Authors:  M Yeshurun; A Gafter-Gvili; M Thaler; N Keller; A Nagler; A Shimoni
Journal:  Infection       Date:  2010-04-28       Impact factor: 3.553

View more
  4 in total

Review 1.  Therapy of Infections due to Carbapenem-Resistant Gram-Negative Pathogens.

Authors:  Chang-Seop Lee; Yohei Doi
Journal:  Infect Chemother       Date:  2014-09-24

2.  Risk factors for mortality in patients with Stenotrophomonas maltophilia bacteremia.

Authors:  Yong Duk Jeon; Woo Yong Jeong; Moo Hyun Kim; In Young Jung; Mi Young Ahn; Hea Won Ann; Jin Young Ahn; Sang Hoon Han; Jun Yong Choi; Young Goo Song; June Myung Kim; Nam Su Ku
Journal:  Medicine (Baltimore)       Date:  2016-08       Impact factor: 1.889

3.  Clinical Characteristics of Stenotrophomonas maltophilia Bacteremia: A Regional Report and a Review of a Japanese Case Series.

Authors:  Hirotaka Ebara; Hideharu Hagiya; Yuto Haruki; Eisei Kondo; Fumio Otsuka
Journal:  Intern Med       Date:  2017-01-15       Impact factor: 1.271

4.  The Difficulty in Administering Appropriate Antimicrobial Therapy for Stenotrophomonas maltophilia Bacteremia.

Authors:  Mitsuru Yanai; Yoshinori Inagaki; Tomohiko Tokunaga
Journal:  Intern Med       Date:  2017-09-15       Impact factor: 1.271

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.